Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

This study is testing a combination of two targeted drugs — befotertinib and icotinib — in people with advanced or metastatic non-small cell lung cancer (NSCLC) that carries uncommon EGFR gene mutations. Most EGFR-targeted drugs work best for common mutations; this study specifically targets rarer mutation types that are harder to treat. **You may be eligible if...** - You are 18 or older - You have a confirmed adenocarcinoma of the lung (a specific cell type of lung cancer) - Your cancer is locally advanced or metastatic (stage IIIB, IIIC, or IV) and cannot be cured by surgery or radiation - Your tumor has an uncommon EGFR mutation (your doctor can test for this with a molecular test) **You may NOT be eligible if...** - You have common EGFR mutations (exon 19 deletion or L858R) - Your cancer is a different cell type (squamous or small cell) - Your cancer has spread to the brain in a way that is unstable or untreated - You have serious heart, liver, or lung problems Talk to your doctor to see if this trial is right for you.